Identification of Novel Autoantibodies Based on the Human Proteomic Chips and Evaluation of Their Performance in the Detection of Gastric Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 15

PMID 33718231

Citations 8

Authors

Chi Cui

Yaru Duan

Cuipeng Qiu

Peng Wang

Guiying Sun

Hua Ye

Liping Dai

Zhuo Han

Chunhua Song

Kaijuan Wang

Jianxiang Shi

Jianying Zhang

Affiliations

Soon will be listed here.

Abstract

Autoantibodies against tumor-associated antigens (TAAbs) can be used as potential biomarkers in the detection of cancer. Our study aims to identify novel TAAbs for gastric cancer (GC) based on human proteomic chips and construct a diagnostic model to distinguish GC from healthy controls (HCs) based on serum TAAbs. The human proteomic chips were used to screen the candidate TAAbs. Enzyme-linked immunosorbent assay (ELISA) was used to verify and validate the titer of the candidate TAAbs in the verification cohort (80 GC cases and 80 HCs) and validation cohort (192 GC cases, 128 benign gastric disease cases, and 192 HCs), respectively. Then, the diagnostic model was established by Logistic regression analysis based on OD values of candidate autoantibodies with diagnostic value. Eleven candidate TAAbs were identified, including autoantibodies against INPP5A, F8, NRAS, MFGE8, PTP4A1, RRAS2, RGS4, RHOG, SRARP, RAC1, and TMEM243 by proteomic chips. The titer of autoantibodies against INPP5A, F8, NRAS, MFGE8, PTP4A1, and RRAS2 were significantly higher in GC cases while the titer of autoantibodies against RGS4, RHOG, SRARP, RAC1, and TMEM243 showed no difference in the verification group. Next, six potential TAAbs were validated in the validation cohort. The titer of autoantibodies against F8, NRAS, MFGE8, RRAS2, and PTP4A1 was significantly higher in GC cases. Finally, an optimal prediction model with four TAAbs (anti-NRAS, anti-MFGE8, anti-PTP4A1, and anti-RRAS2) showed an optimal diagnostic performance of GC with AUC of 0.87 in the training group and 0.83 in the testing group. The proteomic chip approach is a feasible method to identify TAAbs for the detection of cancer. Moreover, the panel consisting of anti-NRAS, anti-MFGE8, anti-PTP4A1, and anti-RRAS2 may be useful to distinguish GC cases from HCs.

Citing Articles

Dephosphorylation-related signature predicts the prognosis of papillary renal cell carcinoma.

Feng J, Jiang L, Tang H, Si Y, Luo L, Liu J Transl Cancer Res. 2024; 13(11):5983-5994.

PMID: 39697703 PMC: 11651751. DOI: 10.21037/tcr-24-669.

Humoral immune response to tumor-associated antigen Ubiquilin 1 (UBQLN1) and its tumor-promoting potential in lung cancer.

Wang Y, Ouyang S, Liu M, Si Q, Zhang X, Zhang X BMC Cancer. 2024; 24(1):283.

PMID: 38431566 PMC: 10908023. DOI: 10.1186/s12885-024-12019-w.

ASPSCR-1 and Sirt-5 alleviate Clonorchis liver fluke rCsNOSIP-induced oxidative stress, proliferation, and migration in cholangiocarcinoma cells.

Bian M, Li S, Zhou H, Bi L, Shen Y, Tingjin C PLoS Negl Trop Dis. 2023; 17(11):e0011727.

PMID: 37948465 PMC: 10664913. DOI: 10.1371/journal.pntd.0011727.

Successful targeting in situ of an oncogenic nuclear antigen by hapten induced tumor associated autoantibodies (iTAA).

Yu B, Zhang J, Fu Q, Han Y, Zhang J, Gao F Sci Rep. 2023; 13(1):9902.

PMID: 37336938 PMC: 10279707. DOI: 10.1038/s41598-023-36757-2.

Identification and evaluation of novel serum autoantibody biomarkers for early diagnosis of gastric cancer and precancerous lesion.

Zhu Q, He P, Zheng C, Chen Z, Qi S, Zhou D J Cancer Res Clin Oncol. 2023; 149(11):8369-8378.

PMID: 37079049 DOI: 10.1007/s00432-023-04732-z.

References

Wang S, Qin J, Ye H, Wang K, Shi J, Ma Y . Using a panel of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of gastric cancer. Oncoimmunology. 2018; 7(8):e1452582. PMC: 6136883. DOI: 10.1080/2162402X.2018.1452582. View

Liu W, Peng B, Lu Y, Xu W, Qian W, Zhang J . Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 2010; 10(6):331-5. PMC: 3119819. DOI: 10.1016/j.autrev.2010.12.002. View

Valesini G, Gerardi M, Iannuccelli C, Pacucci V, Pendolino M, Shoenfeld Y . Citrullination and autoimmunity. Autoimmun Rev. 2015; 14(6):490-7. DOI: 10.1016/j.autrev.2015.01.013. View

Qiu M, Wang Z, Zhou Y, Yang D, Wang F, Xu R . Proposal for a New TNM Stage based on the 7 and 8 American Joint Committee on Cancer pTNM Staging Classification for Gastric Cancer. J Cancer. 2018; 9(19):3570-3576. PMC: 6171027. DOI: 10.7150/jca.26351. View

Old L, Chen Y . New paths in human cancer serology. J Exp Med. 1998; 187(8):1163-7. PMC: 2212229. DOI: 10.1084/jem.187.8.1163. View

Zayakin P, Ancans G, Silina K, Meistere I, Kalnina Z, Andrejeva D . Tumor-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer. 2012; 132(1):137-47. DOI: 10.1002/ijc.27667. View

Qiu C, Wang P, Wang B, Shi J, Wang X, Li T . Establishment and validation of an immunodiagnostic model for prediction of breast cancer. Oncoimmunology. 2020; 9(1):1682382. PMC: 6959442. DOI: 10.1080/2162402X.2019.1682382. View

Huang Y, Zhu H . Protein Array-based Approaches for Biomarker Discovery in Cancer. Genomics Proteomics Bioinformatics. 2017; 15(2):73-81. PMC: 5414965. DOI: 10.1016/j.gpb.2017.03.001. View

Wang X, Zhang Y, Sun L, Wang S, Nie J, Zhao W . Evaluation of the clinical application of multiple tumor marker protein chip in the diagnostic of lung cancer. J Clin Lab Anal. 2018; 32(8):e22565. PMC: 6817050. DOI: 10.1002/jcla.22565. View

10.

Tan H, Low J, Lim S, Chung M . Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009; 276(23):6880-904. DOI: 10.1111/j.1742-4658.2009.07396.x. View

11.

Ceriani R, Sasaki M, Sussman H, Wara W, Blank E . Circulating human mammary epithelial antigens in breast cancer. Proc Natl Acad Sci U S A. 1982; 79(17):5420-4. PMC: 346909. DOI: 10.1073/pnas.79.17.5420. View

12.

Zhang J, Casiano C, Peng X, Koziol J, Chan E, Tan E . Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003; 12(2):136-43. View

13.

Vormittag R, Simanek R, Ay C, Dunkler D, Quehenberger P, Marosi C . High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol. 2009; 29(12):2176-81. DOI: 10.1161/ATVBAHA.109.190827. View

14.

Kobayashi M, Katayama H, Fahrmann J, Hanash S . Development of autoantibody signatures for common cancers. Semin Immunol. 2020; 47:101388. DOI: 10.1016/j.smim.2020.101388. View

15.

Stephens B, Han H, Gokhale V, Von Hoff D . PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther. 2005; 4(11):1653-61. DOI: 10.1158/1535-7163.MCT-05-0248. View

16.

Battistelli S, Stefanoni M, Lorenzi B, DellAvanzato R, Varrone F, Pascucci A . Coagulation factor levels in non-metastatic colorectal cancer patients. Int J Biol Markers. 2008; 23(1):36-41. View

17.

Casiano C, Mediavilla-Varela M, Tan E . Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics. 2006; 5(10):1745-59. PMC: 2790463. DOI: 10.1074/mcp.R600010-MCP200. View

18.

Anderson K, Cramer D, Sibani S, Wallstrom G, Wong J, Park J . Autoantibody signature for the serologic detection of ovarian cancer. J Proteome Res. 2014; 14(1):578-86. PMC: 4334299. DOI: 10.1021/pr500908n. View

19.

Hanayama R, Tanaka M, Miyasaka K, Aozasa K, Koike M, Uchiyama Y . Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science. 2004; 304(5674):1147-50. DOI: 10.1126/science.1094359. View

20.

Li Y, Yang Y, Lu M, Shen L . Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology. 2011; 58(112):2166-70. DOI: 10.5754/hge11753. View